Extremely long tumor retention, on-demand releasing nano-taxel for eradicating ovarian cancers
Ended Project Grant Awarded Last action
- Award ID
- R44CA228645
- Recipient
-
Theranostec Inc. UEI C1B4H9JHQ3J6
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,291,539
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Sacramento, CA 95817, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,496,599 | |
| Amendment | $0 | |
| Amendment | $503,046 | |
| Amendment | $0 | |
| Original award | $291,894 |
Quick answers
Who received award R44CA228645?
R44CA228645 was awarded to Theranostec Inc. by National Cancer Institute (National Institutes of Health) on August 30, 2018.
How much is award R44CA228645 worth?
$2,291,539 has been obligated on R44CA228645.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award